Preoperative Immunotherapy Combined with Chemotherapy for Triple-Negative Breast Cancer: Perspective on the KEYNOTE-522 Study
Open Access
- 10 March 2023
- journal article
- editorial
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (6) , 3166-3169
Abstract
No abstract availableFunding Information
- Rob and Karen Hale Distinguished Chair in Surgical Oncology
- National Institutes of Health (1K08CA259533-01A1)
This publication has 20 references indexed in Scilit:
- Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast CancerJAMA Oncology, 2020
- Pembrolizumab for Early Triple-Negative Breast CancerNew England Journal of Medicine, 2020
- B cells are associated with survival and immunotherapy response in sarcomaNature, 2020
- B cells and tertiary lymphoid structures promote immunotherapy responseNature, 2020
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast CancerNew England Journal of Medicine, 2018
- Safety and Feasibility of Lung Resection After Immunotherapy for Metastatic or Unresectable TumorsThe Annals of Thoracic Surgery, 2018
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combinationNature Reviews Clinical Oncology, 2016
- Immunological Insights from Patients Undergoing Surgery on Ipilimumab for Metastatic MelanomaAnnals of Surgical Oncology, 2013
- Triple-Negative Breast Cancer: Clinical Features and Patterns of RecurrenceClinical Cancer Research, 2007
- Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer StudyJAMA, 2006